- Home
- MTNB vs LIXT Comparison
MTNB vs LIXT Comparison
Compare MTNB & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- LIXT
- Stock Information
- Founded
- MTNB 2013
- LIXT 2005
- Country
- MTNB United States
- LIXT United States
- Employees
- MTNB N/A
- LIXT N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- MTNB Health Care
- LIXT Health Care
- Exchange
- MTNB Nasdaq
- LIXT Nasdaq
- Market Cap
- MTNB 3.6M
- LIXT 4.1M
- IPO Year
- MTNB N/A
- LIXT N/A
- Fundamental
- Price
- MTNB $0.83
- LIXT $1.41
- Analyst Decision
- MTNB Hold
- LIXT
- Analyst Count
- MTNB 1
- LIXT 0
- Target Price
- MTNB N/A
- LIXT N/A
- AVG Volume (30 Days)
- MTNB 354.4K
- LIXT 20.1K
- Earning Date
- MTNB 05-15-2025
- LIXT 05-12-2025
- Dividend Yield
- MTNB N/A
- LIXT N/A
- EPS Growth
- MTNB N/A
- LIXT N/A
- EPS
- MTNB N/A
- LIXT N/A
- Revenue
- MTNB N/A
- LIXT N/A
- Revenue This Year
- MTNB N/A
- LIXT N/A
- Revenue Next Year
- MTNB N/A
- LIXT N/A
- P/E Ratio
- MTNB N/A
- LIXT N/A
- Revenue Growth
- MTNB N/A
- LIXT N/A
- 52 Week Low
- MTNB $0.47
- LIXT $1.02
- 52 Week High
- MTNB $9.60
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- MTNB 60.02
- LIXT 56.67
- Support Level
- MTNB $0.77
- LIXT $1.16
- Resistance Level
- MTNB $1.17
- LIXT $1.48
- Average True Range (ATR)
- MTNB 0.12
- LIXT 0.12
- MACD
- MTNB -0.00
- LIXT 0.00
- Stochastic Oscillator
- MTNB 30.72
- LIXT 69.44
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.